Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.

doi:10.18632/oncotarget.7138

中山醫學大學機構典藏 CSMUIR > 口腔醫學院 > 牙醫學系暨碩士班 > 期刊論文 > Item 310902500/15731

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/15731

Title:	Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Authors:	HL, Cheng;CW, Lin;JS, Yang;MJ, Hsieh;SF, Yang;KH, Lu
Contributors:	中山醫大口腔科學研究所
Keywords:	Rho A;U2OS;geranylgeranylation;metastasis;zoledronate
Date:	2016-03-01
Issue Date:	2016-08-11T03:52:18Z (UTC)
ISSN:	1949-2553
Abstract:	Zoledronate is a standard treatment for preventing skeletal complications of osteoporosis and some types of cancer associated with bone metastases, but we little know whether the effect of zoledronate on metastasis of osteosarcoma. Here, we investigated the inhibitory effects of zoledronate on cell viability, motility, migration and invasion of 4 osteosarcoma cell lines (Saos2, MG-63, HOS and U2OS) by affecting cell morphology, epithelial-mesenchymal transition (EMT) and cytoskeletal organization as well as induction of E-cadherin and reduction of N-cadherin with activation of transcription factors Slug and Twist, especially in U2OS cells. Zoledronate decreased JNK and p38 phosphorylation and upper streams of focal adhesion kinase (FAK) and Src to suppress the motility, invasiveness and migration of U2OS cells. In addition to zoledronate-inhibited Rho A and Cdc42 membrane translocation and GTPγS activities, the anti-metastatic effects in U2OS cells including inhibition of adhesion were reversed by geranylgeraniol, but not farnesol. In conclusion, Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cell-matrix and cell-cell interactions, migration potential, the invasive activity, and the adhesive ability by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
URI:	http://dx.doi.org/10.18632/oncotarget.7138 https://ir.csmu.edu.tw:8080/ir/handle/310902500/15731
Relation:	Oncotarget. 2016 Mar 1;7(9):9742-58
Appears in Collections:	[牙醫學系暨碩士班] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	459	View/Open

View Licence

Loading...